11/15/18 Ruxolitinib Moves On Without Me
I started the BATCC clinical trial on ruxolitinib on June 17, 2016. It was a two year trial designed test the effectiveness of ruxolitinib on alleviating the symptoms of CLL (fatigue, bone pain, joint pain, and others) by targeting cells that carried the JAK-7 enzyme, which produces inflammation. Inflammation is the source of many diseases…